Korean dementia treatment stocks Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
08:30
Jan 21
Jan 21
Biotech suffers as rates hit growth.
Biotech was the hardest-hit area in the rate-driven selloff, with obesity-treatment and dementia-treatment stocks broadly falling. Lee treats this as evidence that rising long-term yields are pressuring high-duration healthcare/growth names in Korea.
MED
About Korean dementia treatment stocks Investor Commentary
Across the available history and selected sources, Buzzberg tracks Korean dementia treatment stocks across 1 sources: 0 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Lee Dong-geun.